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Abstract: Numerous genetic loci have been identified as being associated with circulating fatty
acid (FA) levels and/or inflammatory biomarkers of cardiovascular health (e.g., C-reactive protein).
Recently, using red blood cell (RBC) FA data from the Framingham Offspring Study, we conducted
a genome-wide association study of over 2.5 million single nucleotide polymorphisms (SNPs) and
22 RBC FAs (and associated ratios), including the four Omega-3 FAs (ALA, DHA, DPA, and EPA).
Our analyses identified numerous causal loci. In this manuscript, we investigate the extent to which
polyunsaturated fatty acid (PUFA) levels moderate the relationship of genetics to cardiovascular
health biomarkers using a genome-wide interaction study approach. In particular, we test for
possible gene–FA interactions on 9 inflammatory biomarkers, with 2.5 million SNPs and 12 FAs,
including all Omega-3 PUFAs. We identified eighteen novel loci, including loci which demonstrate
strong evidence of modifying the impact of heritable genetics on biomarker levels, and subsequently
cardiovascular health. The identified genes provide increased clarity on the biological functioning and
role of Omega-3 PUFAs, as well as other common fatty acids, in cardiovascular health, and suggest
numerous candidate loci for future replication and biological characterization.
Keywords: fatty acids; omega-3; alpha linoleic acid; docosahexaenoic acid; inflammatory biomarkers;
cardiovascular disease
1. Introduction
Genome-wide association studies (GWAS) have been previously used to identify common single
nucleotide polymorphisms (SNPs) associated with fatty acid (FA) levels [1,2].There have also been
studies showing correlations between FA levels, specifically Omega-3 and Omega-6 FAs, and a variety
of disease phenotypes and risk factors, including total mortality [3], acute coronary syndrome [4,5],
serum lipid levels [6], cognitive function [7], brain size [8,9], and inflammatory biomarkers [10].
Such biomarkers, including C-reactive protein, are known risk factors of cardiovascular disease [11].
Though studies exist that examine the influence FAs have on inflammation, the understanding of the
relationship remains incomplete. In particular, there are very few studies of FA–genetic interactions
on inflammatory outcomes. Thus, there is a large gap in our understanding of how and where FAs,
specifically Omega-3 and Omega-6 FAs, modulate genetic risk. Thus, little is known as to how genetics
might alter the optimal dietary FA intake for the individual.
For example, using data from the Framingham Heart Study, a comprehensive, longitudinal study
of cardiovascular health, (a) genes associated with fatty acid levels [2], (b) genes associated with
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inflammatory biomarkers [12–15], and (c) the association between fatty acid levels and inflammatory
biomarkers have been identified [16]. To date, little work has been done to comprehensively integrate
genetic, fatty acid, and inflammatory biomarker data to more precisely articulate the complex
relationship between these factors.
Recently, to help elucidate more complex genetic pathways towards disease processes,
genome-wide interaction studies (GWIS) have been used to attempt to identify specific lifestyle
exposures that may modulate genetic associations with disease outcomes [17]. In the case of FAs and
inflammatory biomarkers, testing for potential interactions between SNPs and FAs on biomarker levels
may provide a more complete picture as to how an individual’s genetics modulate FA levels leading to
differential effects on biomarker levels.
Here, we report a GWIS exploring the interaction between the relative proportions of twelve
FAs with over 2.5 million common (minor allele frequency >1%) SNPs and its relationship with nine
inflammatory biomarkers among participants in the Framingham Heart Offspring Study.
2. Materials and Methods
2.1. Sample
We conducted our analysis on the Offspring Cohort of the Framingham Heart Study (FHS). This
sample consists of the children and spouses of the original FHS cohort, who were recruited in 1971.
Detailed descriptions of the sample are available elsewhere [6,18–20]. The final sample consisted of
2700 individuals as a subset of the Offspring subjects that attended Examination 8 (2005–2008). Written
informed consent was provided by all participants, and the Institutional Review Boards at Boston
University approved the Framingham data collection protocols, while Dordt College approved the
analysis protocol for this manuscript.
2.2. Fatty Acids
We chose to use red blood cell (RBC) samples, because they have been shown to be more
representative of FA levels in other tissues/cells [21], and with mounting evidence that this fatty
acid pool may be less affected by recent fat consumption [3]. The RBC samples were analyzed
for glycerophospholipid FA composition using gas chromatography as previously described [6].
We primarily focused on Omega-3 (n3) and Omega-6 (n6) FAs for this study: eicosapentaenoic acid
(EPA, n3), docosapentaenoic acid- n3 (DPA, n3), docosahexaenoic acid (DHA, n3), alpha-linoleic acid
(ALA, n3), linoleic acid (LA, n6), gamma-linoleic acid (GLA, n6), dihomo-gamma-linoleic acid (DGLA,
n6), arachidonic acid (AA, n6), docosapentaenoic acid-n6 (DPA, n6), docosatetranoic acid (DTA, n6),
eicosadienoic acid (EDA, n6), and oleic acid (OA, n9). Means and standard deviations (SDs) are
provided in Table 1. These twelve FAs were selected because circulating polyunsaturated fatty acids
(PUFA) have been shown to be protective against cardiovascular disease (CVD) [22,23], while the
health impacts of omega-6 PUFAs are still under debate [24,25]. OA was also included in this study
as an exploratory look into the impacts of Omega-9 FAs [26], because it is one of most common FAs
(see Table 1), and because we have previously identified a number of genetic variants associated with
it [2]. The other ten FAs measured in the FHS that are included in this analysis are palmitic acid, stearic
acid, palmitoleic acid, myristic acid, palmitelaidic acid, trans oleic acid, trans linoleic acid, eicosenoic
acid, lingnoceric acid, and nervonic acid, and are also included in Table 1.
Nutrients 2017, 9, 900 3 of 15
Table 1. Summary of the 12 red blood cell (RBC) fatty acids (FAs) measured by the Framingham Heart
Study (FHS) and considered in our analysis.
Fatty Acid Mean (Percent Composition) SD
Oleic acid (OA) 13.900% 1.030%
Eicosadienoic acid (EDA) 0.278% 0.046%
Gamma-linoleic acid (GLA) 0.083% 0.072%
Alpha-linoleic acid (ALA) 0.184% 0.098%
Linoleic acid (LA) 11.100% 1.700%
Dihomo-gamma-linoleic acid (DGLA) 1.596% 0.359%
Arachidonic acid (AA) 16.800% 1.600%
Eicosapentaenoic acid (EPA) 0.732% 0.447%
Docosatetranoic acid (DTA) 3.790% 0.826%
Docosapentaenoic acid-n-6 (DPA_N6) 0.661% 0.189%
Docosapentaenoic acid n-3 (DPA_N3) 2.750% 0.453%
Docosahexaenoic acid (DHA) 4.840% 1.360%
The 10 FAs not analyzed here comprise the additional 55% of fatty acid levels (%, standard deviation (SD)): myristic
acid (0.306, 0.08), palmitic acid (21.270, 1.248), palmitelaidic acid (0.167, 0.047), palmitoleic acid (0.359, 0.194),
stearic acid (18.108, 0.947), trans oleic acid (1.649, 0.55), trans linoleic acid (0.253, 0.084), eicosenoic acid (0.277,
0.109), lingnoceric acid (0.732, 0.447), and nervonic acid (0.445, 0.151). The mean and standard deviation of percent
composition are provided for the n = 2703 individuals.
2.3. Biomarkers of Inflammation
Biomarkers were analyzed using commercially available assays by labs affiliated with the
Framingham Heart Study. Their collection, storage, distribution, and measurement procedures are
publicly available in their FHS Inflammatory Marker Manuals [27]. Nine inflammatory biomarkers
were included in this analysis: C-reactive protein (CRP), Intercellular adhesion molecule 1 (ICAM),
Cellular adhesion molecule (CAM), Interleukin-6 (IL6), Lipoprotein-Associated Phospholipase A2
(LP-PLA2 activity denoted by “PLAC”), Monocyte chemoattractant protein-1 (MCP1), Osteoprotegerin
(OPG), P-Selectin, and Tumor necrosis factor receptor II (TNF). These biomarkers were selected based
on their identified association with CVD risk [16,28–35].
2.4. Genotype Data
Genotypes were originally measured using the Affymetrix 500K chip as previouslydescribed [2].
We imputed these markers on the University of Michigan imputation server [36] using the HAPMAP 2
reference panel, yielding approximately 2.5 million variants meeting standard quality control criteria
and with minor allele frequency (MAF) >1% [37,38]. After imputation, variants were assigned
rsIDs and genes based on chromosomal position from build 37 and Ensemble release 75, based
on GRCHh37.p13 [39].
2.5. Statistical Analysis
Regression was used to predict the log-transformed value of each biomarker. We fit a model as
Biomarker = β0 + β1SNP+ β2FA+ β3SNP ∗ FA+ Age+ Sex, where SNP takes a value 0, 1, or 2 based
on the number of minor alleles present for the individual at the SNP being modeled (or, potentially,
a fractional value between 0 and 2 for imputed SNPs). Windsorization was used to reduce the
impact of outliers in FAs and biomarkers, by using values four SDs from the mean in cases where
observed values were more than four SDs from the mean. The model was fit for each SNP–FA
combination separately. Single marker tests were deemed statistically significant when the p-value
for the interaction term in the model was less than 5 × 10–8, a standard criterion for genome-wide
significance [40]. Significance of the interaction term indicates that the interaction between the SNP
and FA adds significantly more explanation of biomarker levels than the SNP and FA alone. A follow
up analysis fit the model Biomarker = β0 + β1SNP for each SNP in order to evaluate whether an SNP
would have been identified as important and related to the biomarker without considering fatty acid
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values in the analysis. LocusZoom [41] was used to generate figures depicting statistical significance,
linkage disequilibrium (LD) structure, and gene locations. Genomic control lambdas (λGC) were
estimated and Q-Q plots were computed. λGC values showed no evidence of overinflation of test
statistics [42]. Less than 1% of the sample was dropped from any particular analysis due to missing
data (genetic, FA, or biomarker data).
3. Results
The clinical characteristics for the FHS Offspring cohort participants have been previously
reported along with their FA levels, and so are not described in detail here [2]. Briefly, the mean
(SD) age was 66 (9) years, 54% were female, 9% smoked, 49% were treated for hypertension, and 43%
were being treated for high cholesterol. Fourteen percent of the sample was diabetic, 11% had coronary
heart disease, and 3% had congestive heart failure.
In total, we identified eighteen unique genome-wide significant (p < 5 × 10–8) SNP by FA
interaction terms (Table S1). No single SNP was significant for more than one biomarker. Six of
the nine biomarkers had significant interactions (all except OPG, PLAC, and P-selectin). Seven of the
FAs under consideration in our analysis had no interactions with any SNPs reach the genome-wide
significance level (DPA(N3), EPA, AA, DGLA, DTA, GLA, and LA), but the other five FAs had at least
one interaction with a SNP reach genome-wide significance, including two Omega-3 FAs (ALA and
DHA). In subsequent discussion about the result, the biomarker levels are reported as pg/mL, and the
FA levels are reported as percent composition.
We have summarized these results by focusing on distinct regions (1 MB or smaller) containing
the significant interactions. Table 2 provides an overview of the eight 1 MB regions covering
the 18 identified SNPs, summarizing location information, the number of significantly associated
interactions, references to prior literature about the functionality of the region, and a listing of the
associated biomarkers.
Table 2. Summary of eight regions (1MB or less) of significant SNP × FA interactions.
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SNP, single nucleotide polymorphism; EAF, effect allele frequency. The genes that the significant interaction SNP
is in or near (50 KB pair range on each side) is reported. Prior GWAS evidence is reported based on a search at
http://www.ebi.ac.uk/gwas/. The column “Significant without interaction” indicates whether the SNP alone
would have reached genome-wide significance if the FA interaction term was not in the model.
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3.1. Chromosome 1: CHRM3
Two significant interactions contain SNPs located within the CHRM3 gene (239,549,865 to
240,078,750). These SNPs (rs16838623 and rs16832149), when interacting with ALA, become
significantly associated with the IL6 biomarker, with p-values of 4.66 × 10–8 and 4.95 × 10–8,
respectively. The average effect allele frequency for the two SNPs is 0.0225, and both SNP × FA
interactions have an estimated slope of approximately 0.9. This means that for every additional copy of
either of the effect alleles, IL6 log-transformed levels increase by about 0.9 due to a higher ALA impact.
See Figure 1 for an illustration of the LD structure and significance of SNPs in the CHRM3 gene.
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Figure 2. An interaction plot between ALA and rs16838623 predicting IL6 levels. This figure shows
the modulating effects the genotype has on FAs and the effect that interaction has on biomarker levels.
The rare homozygote is not included in this plot because, in our sample, there is only one individual
with that genotype.
3.2. Chromosome 2: RPL7P61
There are four significant interactions whose SNPs are near the RPL7P61 gene, which is located
from bp 164,008,761 to 164,009,817 on chromosome 2. When interacting with DHA, these SNPs are
associated with IL6, giving p-values that range from 8.88 × 10–9 to 3.05 × 10–9, with an average effect
allele freque cy f approximately 0.016. The effect size for the interaction ranges from 3.02 to 3.11,
meaning that the impact of DHA on the log-transformed IL6 levels increases by about 3 for every
additional copy of the effect allele.
Figure 3 shows another interaction between SNP rs12623456 and DHA to predict IL6. In this
interaction, the trends are the opposite of what they are for Figure 2. With no copies of the effect allele,
there is very little change i IL6 levels as DHA levels increase. As soon as a copy of the allele is added,
the increase in FA level corresponds overall to an increase in IL6 levels. However, due to the low effect
allele frequency for this SNP (0.0161), the trend for when there are two copies of the effect allele is not
attainable with our sample size.
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Figure 3. An interaction plot between DHA and rs12623456 predicting IL6 levels. This figure shows the
modulating effects the genotype has on FAs and the effect that interaction has on biomarker levels. The rare
homozygote is not included in this plot because, in our sample, there are no individuals with that genotype.
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3.3. Chromosome 3: RP11-373E16.1
The RP11-373E16.1 gene, located from 170,371,635 to 170,372,048, contains two SNPs (rs7611820
and rs9856712) that interact with OA to predict MCP1 levels. The p-values range from 5.87 × 10–10
to 5.25 × 10–10. The average effect allele frequency for the two SNPs is approximately 0.072 and the
average effect size for the interactions is −1.318, which means that for every additional copy of either
effect allele, the impact OA has on log-transformed MCP1 levels decreases by about 1.318.
3.4. Chromosome 7: CHCHD3
There are two SNPs in chromosome 7 that, when interacting with DPA(N6), are significantly
associated with ICAM, giving p-values of 1.07 × 10–8 and 1.00 × 10–8 (rs17424227 and rs17424324).
Both SNPs are near the CHCHD3 gene (132,469,629 to 132,469,629). The average effect allele frequency
for the two SNPs is 0.116. The impact DPA(N6) has on the log-transformed levels of ICAM decreases
by about 0.29 for every additional copy of the effect allele.
3.5. Chromosome 13: LOC105370115
One SNP (rs17079653), near the LOC105370115 gene on chromosome 13, contributes in an
interaction with OA to predict TNF levels with a p-value of 2.88 × 10–8. The effect allele for the
SNP is 0.0233, and the effect size for the interaction is −15.49. Thus, for every additional copy of the
effect allele, the impact OA has on log transformed TNF levels decreases by 15.49.
3.6. Chromosome 14
3.6.1. LOC105378178
In chromosome 14, there is one interaction with EDA and the SNP rs7160151 that is significantly
associated with CRP at a p-value of 2.93 × 10–8. The SNP in this interaction is located near the
LOC105378178 gene. The SNP has an effect allele frequency of 0.29, and the effect size for the interaction
is 1.19, meaning that for each additional copy of the effect allele, log-transformed CRP levels increase
by 1.19 due to the increased impact of EDA.
3.6.2. CTD-3006G17.2
There are three SNPs in the CTD-3006G17.2 gene, which is located from 27,727,923 to 28,314,492,
that contribute to a significant interaction. All three interact with OA, and are associated with CAM
with p-values as low as 4.33 × 10–8. Minor allele frequencies are in the 0.25 range for these SNPs.
The effect size of the corresponding interactions for the three is around −0.57. For each additional copy
of the three alleles, the impact OA has on log-transformed CAM levels decreases by about 0.57. Figure 4
shows the linkage disequilibrium and significance pattern of SNPs in and around the SNP rs17112580.
Nutrients 2017, 9, 900 8 of 15
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3.7. Chromosome 20: LINC00652
The LINC00652 gene (18,768,295 to 18,774,979) is in close proximity to three SNPs that, when
interacting with OA, are associated with the CRP biomarker. These interactions have p-values that
range from 4.54 × 10–8 to 3.23 × 10–8. The effect allele frequency for the three corresponding SNPs are
all around 0.048. The effect size for the interactions ranges from 5.129 to 5.215, which means that every
additional copy of any of the effect alleles increases the impact OA has on log-transformed CRP levels
by about 5.15. Figure 5 shows the pattern of significance and LD structure.
Nutrients 2017, 9, 900 9 of 15Nutrients 2017, 9, x FOR PEER REVIEW  9 of 15 
 
levels by about 5.15. Figure 5 shows the pattern of significance and LD structure.
 
Figure 5. LocusZoom Plot for rs3762220. This figure shows the linkage disequilibrium and 
significance pattern of SNPs in and around the SNP rs3762220. 
4. Discussion 
In previous analyses on this sample, we did not consider potential moderating effects of SNPs 
on the associations between fatty acids and inflammatory biomarkers, as we have done here. Notably, 
none of the SNPs we identified have been previously associated with inflammatory biomarkers or 
with fatty acid levels. Without including the interaction term in our models, none of the SNPs 
contributing to the interaction would have been discovered. Our results confirm the utility of 
interaction studies and provide specific interactions to investigate further. 
We focus the remainder of our discussion on the eighteen loci that show strong evidence of an 
interaction with five separate FAs (DPA(N6), EDA, OA, ALA, and DHA) on inflammatory 
biomarkers. DPA(N6) and EDA have been somewhat understudied in the literature; however, there 
is a study that associates increased amounts of long-chain Omega-6 fatty acids with lower risk for 
CVD, which includes both DPA(N6) and EDA [43], and EDA was observed in vitro to modulate the 
metabolism of other FAs and therefore the inflammatory response [44]. A recent study indicated that 
OA plays a protective role against cardiovascular health, and has been shown to improve endothelial 
dysfunction when inflammatory signals are present, thus stabilizing arteries’/veins’ response to 
adverse immune response [45,46]. ALA has previously been shown to be associated with CVD risk 
[47,48]. Finally, DHA is an Omega-3 fatty acid that has been associated with cardiovascular disease 
risk, and evidence suggests that it has anti-arrhythmic and anti-thrombotic effects when consumed 
as a dietary supplement in fish oil pills [49]. 
  
Figure 5. LocusZoom Plot for rs3762220. This figure shows the linkage disequilibrium and significance
pattern of SNPs in and around the SNP rs3762220.
4. iscussion
In previous analyses on this sample, we did not consider potential moderating effects of SNPs on
the associations between fatty acids and inflammatory bio arkers, as e have done here. Notably,
none of the SNPs we identified have been previously associated with inflammatory biomarkers or with
fatty acid levels. Without including the i teractio term in our odels, none of the SNPs contributing
to the interacti n would have been discovered. Our results confirm the tility o interaction studies
a d provide specific inte act on to investigate further.
e the remainder of our discussi on the eighteen loci that h w strong evidence
of an interaction with five separate FAs (DPA(N6), EDA, O , LA, and DHA) on inflammatory
bio r e so e hat understudied in the literature; however, there
is a st t t ts of long-chain Omega-6 fatty acids with lowe risk for
, i [43], and EDA was observed in vitro to modulate the
eta lis i fl atory response [44]. A recent study indicated that
l t ti l i t r i sc lar health, and has b en shown to improv endothelial
sf ti i fl t r si ls r r s t, t s st ilizi g rteries’/veins’ response to
a erse i e response [45,46]. ALA has previously been shown to be associated with CVD
risk [47,48]. Finally, DHA is an Omega-3 fatty acid that has been associated with cardiovascular disease
risk, and evidence suggests that it has anti-arrhythmic and anti-thrombotic effects when consumed as
a dietary supplement in fish oil pills [49].
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4.1. Docosapentaenoic Acid (Omega-6)
There are two SNPs in chromosome 7 that interact with DPA(N6) to predict ICAM. These
SNPs (rs17424324 and rs17424227) are located near the CHCHD3 gene, which codes for an inner
mitochondrial membrane scaffold protein. While CHCHD3 has no prior GWAS evidence, the protein
has been shown to be essential for maintaining crista integrity and mitochondrial function. Crista
structure is very important, as its disruption has been implicated in a variety of cardiovascular and
neurodegenerative diseases. Thus, the interaction of DPA(N6) and SNPs near CHCHD3 may have an
impact on CVD [50].
4.2. Eicosadienoic Acid
A single SNP located in chromosome 14 (rs7160151) showed evidence of interaction with EDA
to predict CRP levels. The SNP is located near the LOC105378178 gene. While no prior GWAS
evidence exists revealing variants within LOC105378178 as associated with cardiometabolic traits,
there is evidence of association with a variety of mental disorders, including ADHD [51] andPTSD [52],
Otherwise, this gene remains relatively uncharacterized.
4.3. Oleic Acid
4.3.1. Chromosome 3
Two interactions contain SNPs located in chromosome 3 that, when interacting with OA, are
associated with MCP1 levels. These SNPs (rs7611820 and rs9856712) are located near the CLDN11
gene. GWAS has shown no evidence of variants within CLDN11 as associated with cardiometabolic
traits. However, the protein CLDN11 codes for is a tight-junction protein, whose deficiency may lead
to cell barrier dysfunction in endothelial cells. Such a deficiency is considered the initiating process
and pathological basis of CVD in diabetes [53].
4.3.2. Chromosome 13
One SNP in chromosome 13 contributes to an interaction with OA to predict TNF levels. This SNP
(rs17079653) is near the SPATA13 gene or spermatogenesis-associated 13 gene. Prior GWAS has shown
that variants in SPATA13 are associated with psychological disorders, such as depression and alcohol
dependence [54]. To date, there are no studies reporting the association of SPATA13 with CVD risk
factors or FA levels.
4.3.3. Chromosome 14
Three interactions, whose SNPs are located in chromosome 14, are associated with CAM levels.
The three SNPs (rs17112580, rs992745, and rs7145681) are near the CTD-3006G17.2, which is a
pseudogene. There is no prior GWAS evidence for variants within CTD-3006G17.2 being associated
with any cardiometabolic traits or other phenotypes.
4.3.4. Chromosome 20
There are three SNPs in chromosome 20 that contribute to interactions with OA that are associated
with CRP levels. The SNPs (rs3762220, rs3827974, and rs3762221) are found near the DTD1 gene,
which codes for a protein associated with the initiation of DNA replication. There is not any prior
GWAS evidence for variants in DTD1 being associated with cardiometabolic traits. There is evidence,
however, that this gene is associated with higher levels of DHA as well as with generally higher
Omega-3 and Omega-6 FA levels [55]. DTD1 also may be a risk factor for aspirin-intolerant asthma
through a mechanism that promotes a pro-inflammatory phenotype [56].
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4.4. Alpha Linoleic Acid
There are two interactions to which ALA contributes in chromosome 1 on IL6. These interactions
are both in the CHRM3 (acetylcholine receptor M3) gene, and predict the IL6 biomarker. Prior evidence
shows that variants in the CHRM3 gene are associated with hypertension [57], obesity-related traits [58],
and platelet count [59]. All three variables involved in this interaction (ALA, IL6, and CHRM3) have
previously been shown to be associated with CVD risk [60–62]. ALA levels have also been shown to be
associated with hypertension [48,63]. Thus, CHRM3, as a receptor known to modulate the production
of cytokines, is a strong candidate for future exploration in the prediction of CVD risk.
4.5. Docosahexaenoic Acid
Four SNPs in chromosome 2 contribute to significant interactions with DHA to predict IL6 levels.
These SNPs are located near the RPL7P61 gene, which is a ribosomal protein pseudogene. Prior
genome-wide association studies have identified variants in RPL7P61 as associated with phospholipid
levels [64] as well as breast cancer survival [65].
4.6. Limitations
While our analysis identified eighteen interactions between genetic loci and FAs to be associated
with biomarker levels, some limitations of our analysis are worth noting. First, our results may be
limited by the low levels of these FAs in the blood. Also, the lack of additional covariates other than age
and sex may affect the results of our analysis. Further work is needed to develop models that leverage
various covariates, including dietary covariates (e.g., consumption and supplementation), that could
mask the impact of some SNPs in our current analysis. Second, our analysis did not look at all FAs
or FA ratios. Investigating interactions between SNPs and FA ratios may give a clearer picture as to
how a genotype modulates FA conversion signifying a few metabolism pathways. We note that this
analysis only analyzed RBC FAs. While RBC FAs may have some advantages (e.g., stability over time),
other FA samples, including circulating free FAs, may reveal different results [66]. Also, our results are
limited to the effects these FAs and their interactions with SNPs have on our nine known inflammatory
biomarkers. Further research is necessary to further investigate additional inflammatory biomarkers
that may have a more direct relationship with FA levels, as well as additional FAs (e.g., saturated
FAs). Next, to date, many of the regions around the loci for the significant interactions are not well
understood. This suggests the need for replication, which could lead to novel biological understanding
if the findings are replicable in other samples. Finally, our focus on common variants (vs. rare) and
linear relationships (vs. non-linear) between SNP × FA interactions and biomarker levels represents
one of many models. These numerous other models are worth exploring in subsequent analyses.
5. Conclusions
Genome-wide interaction studies are becoming a more widely used method to provide valuable
evidence of potential gene–environment interactions’ contributions towards phenotypes of interest.
Fatty acid research, especially with Omega-3 FAs, has shown the importance their contribution has
on the health of an individual. The interactions identified in this analysis provide more information
about specific genes that will contribute to our understanding both of how these genes modulate
FA levels, and of how, together, genes and environment affect an individual’s phenotype. Wet-lab
exploration of these interactions will likely contribute greatly to the understanding of these effects.
Using a meta-analysis to examine larger sample sizes and sequencing data to explore the potential
contribution of rare variants to these interactions are also worthy goals in the future.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/8/900/s1,
Table S1: Summary of eighteen significant interactions.
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